NCT06564116View on ClinicalTrials.gov

Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above

PHASE4CompletedINTERVENTIONAL
Enrollment

612

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

March 28, 2024

Study Completion Date

March 28, 2024

Conditions
Hepatitis E
Interventions
BIOLOGICAL

Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)

Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.

BIOLOGICAL

Recombinant Hepatitis E Vaccine (Escherichia Coli)

Participants would receive 3 doses of licensed hepatitis E vaccine intramuscularly at month 0, 1 and 6

Trial Locations (1)

Unknown

Youxi County Center for Disease Control and Prevention, Sanming

All Listed Sponsors
collaborator

Center for Disease Control and Prevention, Fujian

OTHER

lead

Xiamen Innovax Biotech Co., Ltd

INDUSTRY